Funding for this research was provided by:
cll global research foundation
royal melbourne hospital foundation
Received: 23 June 2021
Accepted: 1 November 2021
First Online: 22 November 2021
: Peripheral blood samples were collected with informed consent from CLL patients at the Peter MacCallum Cancer Centre (project 13/36) and The Royal Melbourne Hospital (Melbourne, Australia—project 2015.128) under ethics approval of the respective institution’s human research ethics committee and in accordance with the Declaration of Helsinki. Peripheral blood samples from age matched Healthy Donors were obtained from the Australian Red Cross Blood Service with ethics approval from the Melbourne Health Human Research Ethics Committee (project 2013.288).
: Not applicable.
: JED, CS, KM: No competing interests. CST: honorarium from Beigene, AbbVie and Janssen. Peter Mac receives research funding from Beigene, AbbVie and Janssen. RMK, DSR: Research funding from BeiGene.